Home Alzheimer’s Disease Larotrectinib Demonstrates Limited Benefit in Patients with NTRK Alterations

Larotrectinib Demonstrates Limited Benefit in Patients with NTRK Alterations

In a data analysis presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting, held from April 27-28, 2020, researchers suggested that larotrectinib (Vitrakvi) is highly effective in patients with NTRK gene fusions and has demonstrated durable responses.1

However, in patients with other non-fusion NTRK alterations, including point mutations and amplifications, larotrectinib offered only limited benefit.

NTRK gene fusions are found at high frequencies at 90% or more in rare tumor types such as secretory breast carcinoma and infantile fibrous sarcoma, and at lower frequencies, generally less than 1%, in a range of other common tumor types, including lung and colorectal cancers,” David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, said in a poster presentation of the data at AACR.2

Data for the trial were pooled from 3 clinical…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments